Industry News
Major Cardiology Review: Every Nicotine Product Impacts Heart Health
A sweeping new review in Nature Reviews Cardiology delivers a message the nicotine world cannot ignore: nicotine itself—not just cigarette smoke—harms blood vessels and the heart across every product category, from combustible cigarettes to vapes and nicotine pouches. Published around August 19 and led by Professor Thomas Münzel of University Medical Center Mainz, it is the first review to pull together mechanistic, biomarker, and clinical evidence across all major nicotine products and rank them on a single harm scale.
What the Science Says
The review's core finding is that nicotine attacks the vascular system through two independent routes. In the endothelium—the vessel's protective inner lining—nicotine suppresses prostacyclin, a natural vasodilator, while triggering endothelin-1, a potent constrictor. In the surrounding smooth muscle, it blocks potassium channels and disrupts calcium handling, directly tightening vessels.
"Nicotine doesn't only disable the vessel's protective lining—it directly tightens the muscle around it," Münzel said.
Add oxidative stress, inflammation, arterial stiffening, and clot-promoting effects, and the authors trace a chain from nicotine receptor to plaque rupture—the primary trigger of heart attacks and strokes.
Crucially, the authors also rank products. Their evidence-graded hierarchy runs from combustible cigarettes and waterpipes (worst) down through heated-tobacco products and e-cigarettes to oral nicotine—chewing tobacco and pouches—at the lower end. Only abstinence carries no risk.
The Honest Middle Ground
This is not an "everything is equally bad" paper, and the distinction is vital. Münzel himself put it plainly: removing combustion clearly reduces harm—but it does not remove it entirely. The authors describe reduced-risk products as sitting "on a continuum of cardiovascular risk, not off it."
They also acknowledge an evidence gap: for pouches, vapes, and heated tobacco, long-term cardiovascular outcome data are still thin. Consequently, the case rests mostly on mechanistic and biomarker studies, whereas cigarettes have decades of clinical evidence behind their record. For consumers, both halves of that message matter:
- A smoker who switches completely to a pouch or vape is, on this review's own hierarchy, moving down the risk ladder.
- A non-user who picks up a pouch because it seems harmless is moving up from zero.
- Nicotine's dependence potential—which the authors note ranks alongside cocaine and heroin—applies either way.
What It Means for the Industry
Expect this review to echo through policy debates. The authors call for regulating products by nicotine content rather than product-by-product—a framing that would touch pouches and vapes currently treated more lightly than cigarettes in many countries. This follows recent trends where regulatory bodies are scrutinizing emerging oral nicotine technologies.
For adults who use tobacco products, the practical takeaways are sharpened: combustion remains the biggest hazard, no product is risk-free, switching completely beats dual use, and quitting entirely beats both. For those who still choose traditional formats, options like filtered cigars or cigarillos remain subject to these same physiological impacts. Anyone with cardiovascular disease or risk factors has a specific, evidence-backed reason to discuss nicotine use with a medical professional.
The Bottom Line
The most comprehensive look yet at nicotine and the heart lands on a two-sided truth: the harm-reduction ladder is real, and every rung on it still carries risk. As pouches take over the backbar, understanding these health implications becomes increasingly vital for the modern consumer.